Ajax Therapeutics Announces Oral and Poster Presentations on Next‑Generation JAK2 Inhibitors at American Society of Hematology Annual Meeting

NEW YORK--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel, selective small molecules for myeloproliferative neoplasms (MPNs), today announced two abstracts have been accepted for oral and poster presentations at the 64^th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022 in New Orleans. The presentations highlight preclinical data on Ajax’s next-generation JAK2 inhibitors for the treatment of MPNs.

ASH 2022 Presentation Details:

Oral Presentation Title: JAK2^V617 Reversible Activation Shows an Essential Requirement for JAK2^V617 in Myeloproliferative Neoplasms (MPNs)
Authors: Andrew Dunbar, MD, Memorial Sloan Kettering Cancer Center (Presenter); Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center (Lead author)
Session Name: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel Therapeutic Targets in MPN and CML
Presentation Date/Time: December 10, 2022, at 5:15 p.m. CST
Location: Ernest N. Morial Convention Center, 275-277

Poster Presentation Title: The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)
Publication Number: 2992
Authors: Shivam Rai, PhD, University Hospital Basel (Switzerland); Alan Futran, PhD, Schrödinger Inc.; Charley Xu, Schrödinger Inc.; Sayan Mondal, PhD, Schrödinger Inc.; Craig Masse, PhD, Ajax Therapeutics, Inc.; Radek C. Skoda, MD, University Hospital Basel; Ross L. Levine, MD, Memorial Sloan Kettering Cancer Center; Andrew Dunbar, MD, Memorial Sloan Kettering Cancer Center
Session Name: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II
Session Date/Time: Sunday, December 11, 2022, 6:00 - 8:00 p.m. CST
Location: Ernest N. Morial Convention Center, Hall D

Abstracts are available on the ASH meeting website at www.hematology.org

About Ajax Therapeutics

Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis. By combining the deep cancer and structural biology insights of our founding scientists with the industry’s most advanced computational drug discovery and protein structure platforms from our founding partner, Schrödinger, Inc., we aim to discover and develop more precisely designed therapies to address significant unmet needs for patients with MPNs.

Please find more information at www.ajaxtherapeutics.com.

NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics. Dr. Levine also has intellectual property rights and interests that MSK has licensed to Ajax. MSK has intellectual property rights and other financial interests related to Ajax.